Denali Therapeutics Inc. (NASDAQ:DNLI) Insider Sells $465,339.78 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander O. Schuth sold 15,558 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Denali Therapeutics Price Performance

DNLI stock traded down $1.69 during mid-day trading on Tuesday, reaching $29.89. The company had a trading volume of 927,180 shares, compared to its average volume of 1,069,046. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $33.33. The company has a market capitalization of $4.30 billion, a price-to-earnings ratio of -11.44 and a beta of 1.40. The stock has a 50 day simple moving average of $27.95 and a two-hundred day simple moving average of $23.73.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business posted ($0.72) EPS. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.62 EPS for the current year.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DNLI. EP Wealth Advisors LLC acquired a new stake in Denali Therapeutics during the first quarter worth approximately $831,000. Edgestream Partners L.P. purchased a new position in shares of Denali Therapeutics in the 1st quarter worth approximately $2,301,000. Swiss National Bank grew its stake in Denali Therapeutics by 0.7% in the 1st quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after purchasing an additional 1,500 shares during the period. Bayesian Capital Management LP purchased a new stake in shares of Denali Therapeutics during the 1st quarter worth approximately $447,000. Finally, Capital Research Global Investors lifted its position in shares of Denali Therapeutics by 107.9% during the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company’s stock valued at $124,145,000 after buying an additional 3,140,429 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Analyst Ratings Changes

DNLI has been the topic of a number of research analyst reports. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Jefferies Financial Group lifted their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Citigroup boosted their price target on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Wedbush cut their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.